PensonPELongDLHowardG, et al.Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. Eur Heart J. 2018;39(40):3641–3653.
2.
Hippisley-CoxJCouplandCVinogradovaY, et al.Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336(7659):1475–1482.
3.
PiepoliMFHoesAWAgewallS, et al.ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–2381.
4.
ShenJShangQTamL-S. Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. Transl Res J Lab Clin Med. 2016;167(1):138–51.
5.
RidkerPMEverettBMPradhanA, et al.Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752–62.
6.
CronsteinBN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57(2):163–72.
7.
RidkerPMEverettBMThurenT, et al.Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.
8.
ChoiHKHernanMASeegerJDRobinsJMWolfeF. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359(9313):1173–7.
9.
SlotO. Methotrexate treatment and mortality in rheumatoid arthritis. Lancet. 2002;360(9339):1095; author reply 7-8.
10.
SinghSFumeryMSinghAG, et al.Comparative risk of cardiovascular events with biologic and synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis [published online ahead of print 15 March 2019]. Arthritis Care Res. 2019. doi:10.1002/acr.23875.
11.
RuscicaMFerriNMacchiCCorsiniASirtoriCR. Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?Ann Med. 2018;50(6):461–84.
12.
BălănescuARBojincăVCBojincăMDonisanTBălănescuSM. Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases. Exp Ther Med. 2019;17(2):1024–9.
13.
Charles-SchoemanCYin LeeYShahbazianA, et al.Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial. Arthritis Rheumatol. 2017;69(1):46–57.
14.
ReissABCarsonsSEAnwarK, et al.Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum. 2008;58(12):3675–83.
15.
HjeltnesGHollanIFørreO, et al.Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor. Clin Exp Rheumatol. 2013;31(3):415–21.
16.
Otocka-KmiecikAMikhailidisDPNichollsSJDavidsonMRyszJBanachM. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?Prog Lipid Res. 2012;51(4):314–24.
17.
KatsikiNAthyrosVGKaragiannisAMikhailidisDP. High-density lipoprotein, vascular risk, cancer and infection: a case of quantity and quality?Curr Med Chem. 2014;21(25):2917–26.
18.
MangoniAABaghdadiLRShanahanEM, et al.Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study. Ther Adv Musculoskelet Dis. 2017;9(9):213–29.
19.
GomesFLTMaranhãoRCTavaresER, et al.Regression of atherosclerotic plaques of cholesterol-fed rabbits by combined chemotherapy with paclitaxel and methotrexate carried in lipid core nanoparticles. J Cardiovasc Pharmacol Ther. 2018;23(6):561–9.
20.
BordyRVerhoevenFTournier-NappeyMWendlingDDemougeotCTotosonP. Methotrexate did not improve endothelial function in rheumatoid arthritis: a study in rats with adjuvant-induced arthritis. Clin Exp Rheumatol. 2019;37(1):81–8.
21.
DayALSinghJA. Cardiovascular disease risk in older adults and elderly patients with rheumatoid arthritis: what role can disease-modifying antirheumatic drugs play in cardiovascular risk reduction?Drugs Aging. 2019;36(6):493–510. doi:10.1007/s40266-019-00653-0
22.
NaranjoASokkaTDescalzoMA, et al.Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthr Res Ther. 2008;10(2):R30.
23.
MichaRImamuraFWyler von BallmoosM, et al.Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362–70.
24.
RoubilleCRicherVStarninoT, et al.The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480–9.
25.
De VecchisRBaldiCPalmisaniL. Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data. Anatol J Cardiol. 2016;16(1):2–9.
26.
PintoMRCKakehasiAMSouzaAJ, et al.Methotrexate use, not interleukin 33, is associated with lower carotid intima-media thickness in patients with rheumatoid arthritis. Adv Rheumatol. 2019;59(1):15.
27.
KitasGDNightingalePArmitageJ, et al.Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): a multicenter randomized, placebo controlled trial. Arthritis Rheumatol. 2019; 71(9):1437–1449. doi:10.1002/art.40892
28.
SoulaidopoulosSNikiphorouEDimitroulasTKitasGD. The role of statins in disease modification and cardiovascular risk in rheumatoid arthritis. Front Med. 2018;5:24.
29.
LiGMZhaoJLiB, et al.The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials. Autoimmun Rev. 2018;17(3):215–25.
30.
GaziIFBoumpasDTMikhailidisDPGanotakisES. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol. 2007;25(1):102–11.
